Clinical Trial: A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07636772) titled 'A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma' on June 04.

Brief Summary: This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.

Study Start Date: June 22

Study Type: INTERVENTIONAL

Condition: Urothelial Carcinoma (UC)

Intervention: DRUG: AK146D1 for injection

AK146D1 for injection is an antiTrop2/Nectin4 bispecific antibody-drug conjugate

DRUG: AK112 Injection

AK112 Injection is a PD-1/VEGF bispecific antibody

Recruitment Status: NOT_Y...